Background: There is high risk of left ventricular hypertrophy (LVH) in hemodialysis
patients and attention is required to address this problem. Till date most of the proteomics studies in
Chronic Kidney Disease (CKD) have been carried out in urine samples and have revealed some
important protein biomarkers.
Objective: The current study was undertaken to evaluate the serum proteomic profile in hemodialysis
patients with LVH.
Methods: The study comprised of 12 hemodialysis patients with evidence of LVH and 12 normal
healthy individuals. The serum samples pooled from cases and normal healthy individuals were subjected
to 2D-DIGE followed by gel analysis. Fifteen spots were selected based on folds of increase or
decrease and uniqueness of the protein spot for further mass spectrum (MS) analysis. The 3D structures
of proteins were predicted using Prime from Schrodinger software. From the MS data, the 1D structure
of protein was assessed through which 2D structure and 3D structure were predicted using in silico
tools. Protein structure validation was done using PROCHECK and ERRAT and further protein interaction
was studied using STRING analysis.
Results: The results data suggest that plasma inflammatory proteins (like Monoclonal antibody CH89
heavy chain (partial), Immunoglobin heavy chain variable region, IgM heavy chain VH1 region precursor),
nuclear related proteins (such as zinc finger protein 224, lethal malignant brain tumor like protein,
mitotic check point) were differentially expressed.
Conclusion: The assessment of serum proteomics in hemodialysis with LVH provides an altered
protein pattern, which may serve as a potential biomarker for monitoring the course of the disease.